Kolistimetatnatrium Xellia for Multidrug-resistant Gram-negative infections
Quick answer: Kolistimetatnatrium Xellia is used for Multidrug-resistant Gram-negative infections as part of a polymyxin antibiotic treatment regimen. Cationic polypeptide that disrupts bacterial outer membrane phospholipids causing cell death The specific dosing for Multidrug-resistant Gram-negative infections is determined by your prescriber based on individual factors.
Why is Kolistimetatnatrium Xellia used for Multidrug-resistant Gram-negative infections?
Kolistimetatnatrium Xellia belongs to the Polymyxin antibiotic class. Cationic polypeptide that disrupts bacterial outer membrane phospholipids causing cell death This action makes it useful for treating or managing Multidrug-resistant Gram-negative infections in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Kolistimetatnatrium Xellia is the right choice for a specific patient depends on the type and severity of Multidrug-resistant Gram-negative infections, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Multidrug-resistant Gram-negative infections
Common adult dosing range: 1-2 million IU IV every 8 hours (CMS); inhaled 1-2 million IU twice daily. The actual dose for Multidrug-resistant Gram-negative infections depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Kolistimetatnatrium Xellia medicine page.
What to expect
Kolistimetatnatrium Xellia treatment for Multidrug-resistant Gram-negative infections typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Multidrug-resistant Gram-negative infections
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Kolistimetatnatrium Xellia is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Polymyxin antibiotic for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Kolistimetatnatrium Xellia
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Kolistimetatnatrium Xellia full prescribing information · All Polymyxin antibiotic alternatives
Frequently asked questions
How effective is Kolistimetatnatrium Xellia for Multidrug-resistant Gram-negative infections?
Effectiveness varies by individual response, dose, and severity. Kolistimetatnatrium Xellia is one of several treatment options for Multidrug-resistant Gram-negative infections, supported by clinical evidence within the polymyxin antibiotic class. Discuss expected response with your prescriber.
How long do I need to take Kolistimetatnatrium Xellia for Multidrug-resistant Gram-negative infections?
Treatment duration depends on the nature of Multidrug-resistant Gram-negative infections — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Kolistimetatnatrium Xellia when used for Multidrug-resistant Gram-negative infections?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Kolistimetatnatrium Xellia for Multidrug-resistant Gram-negative infections?
Yes. Multiple medicines and non-drug options exist for Multidrug-resistant Gram-negative infections. Alternatives within the polymyxin antibiotic class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.